Access cutting-edge pneumococcal infection treatment through this clinical trial at a research site in Madera. Study-provided care at no cost to qualified participants.
Access pneumococcal infection specialists in Madera at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pneumococcal infection treatment provided free
This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatr
Sponsor: Sanofi
Check if you qualify for this pneumococcal infection clinical trial in Madera, CA
If you're searching for pneumococcal infection treatment options in Madera, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Madera research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pneumococcal infection specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.